Rapid, sensitive and specific SARS coronavirus-2 detection: a multi-center comparison between standard qRT-PCR and CRISPR based DETECTR.

Eelke Brandsma*, Han J.M.P. Verhagen*, Thijs J.W. van de Laar, Eric C.J. Claas, Marion Cornelissen and Emile van den Akker

1 Sanquin Research, Department of Hematopoiesis, Amsterdam, The Netherlands, and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
2 Sanquin Research, Department of Donor Medicine Research, Amsterdam, The Netherlands and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
3 Department of Medical Microbiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
4 Department of Medical microbiology, Leiden University Medical Center, Leiden, The Netherlands
5 Department of Medical Microbiology, Amsterdam University Medical Center, Amsterdam, The Netherlands

Correspondence to:
Emile van den Akker (PhD)
Department of Hematopoiesis
Sanquin Research
Plesmanlaan 125, 1066 CX
Amsterdam, The Netherlands
phone:0031(0)631010473
e-mail: e.vandenakker@sanquin.nl

*contributed equally

Key points
SARS-CoV-2 detection using DETECTR is for 95% in concordance with qRT-PCR.
DETECTR is highly specific for SARS-CoV-2 and equally sensitive compared to qRT-PCR.
DETECTR-point of care and DETECTR-high throughput represent independent alternatives to qRT-PCR platforms for SARS-CoV-2 detection.
Abstract

Recent advances in CRISPR-based diagnostics suggest that DETECTR, a combination of isothermal reverse transcriptase loop mediated amplification (RT-LAMP) and subsequent Cas12 bystander nuclease activation by amplicon targeting ribonucleoprotein complexes, could be a faster and cheaper alternative to qRT-PCR without sacrificing sensitivity/specificity.

Here we compare DETECTR with qRT-PCR to diagnose COVID-19 on 378 patient samples.

Patient sample dilution assays suggest a higher analytical sensitivity of DETECTR compared to qRT-PCR, however, this was not confirmed in this large patient cohort, were we report 95% reproducibility between the two tests. These data showed that both techniques are equally sensitive in detecting SARS-CoV-2 providing additional value of DETECTR to the currently used qRT-PCR platforms. For DETECTR, different gRNAs can be used simultaneously to obviate negative results due to mutations in N-gene. Lateral flow strips, suitable as a point of care test (POCT), showed a 100% correlation to the high-throughput DETECTR assay. Importantly, DETECTR was 100% specific for SARS-CoV-2 relative to other human coronaviruses.

As there is no need for specialized equipment, DETECTR could be rapidly implemented as a complementary technically independent approach to qRT-PCR thereby increasing the testing capacity of medical microbiological laboratories and relieving the existent PCR-platforms for routine non-SARS-CoV-2 diagnostic testing.

Key words: COVID-19, SARS-CoV-2, DETECTR, qRT-PCR,
Introduction

SARS Coronavirus-2 (SARS-CoV-2), the causative agent for coronavirus disease 2019 (COVID-19), emerged in December 2019 in Wuhan, China and caused a pandemic. As of July 19th 2020, over 14 million confirmed SARS-CoV-2 infections and more than 600,000 COVID-19 related deaths have been reported worldwide. To curb this epidemic, effective prevention and control measures including the early identification of SARS-CoV-2 infected individuals, are crucial. Outbreak management is hampered by the high transmissibility and broad spectrum of clinical features of SARS-CoV-2. Severe illness marked by pneumonia, acute respiratory distress syndrome (ARDS) and the need for mechanical ventilation is strongly skewed towards people over 70 years old and those with underlying diseases. Many others experience only mild to moderate symptoms such as fever, fatigue, (dry) cough and/or dyspnoea or do not have complaints at all[1].

Infection surveillance and notification play an important role in outbreak prevention and control. As many infections may go unnoticed, large-scale availability of reliable diagnostic tests also for those with mild symptoms is of critical importance to protect especially those at highest risk of developing severe illness. Accurate monitoring of the SARS-CoV-2 epidemic curve helps estimating future disease burden and serves as an important societal impact parameter for pre-emptive policy making e.g. with regards to the justification of less or more restrictive quarantine measures and prevention of health-care system overflow[2–4]. Reverse transcriptase polymerase chain reaction (RT-PCR) is the current diagnostic standard for the detection of SARS-CoV-2. Despite its high sensitivity and specificity, qRT-PCR requires (expensive) specialized equipment, trained staff, and has a relative long turn-around-time (TAT; 2–4 hours). In the Netherlands, the strong dependence on qRT-PCR caused a shortage of reagents and consumables during the pandemic, which limited the test-capacity and resulted in possibly suboptimal outbreak management.

Isothermal reverse transcriptase loop mediated isothermal amplification (RT-LAMP) in combination with Cas12 detection does not need expensive specialized equipment, is highly sensitive and specific,
has a short TAT and is easy to implement and therefore could be used as an alternative for qRT-PCR [5,6]. This technology is termed DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR). The single strand DNA nuclease activity of Cas12 can generate a high-throughput SARS-CoV-2 point-of-care test (POCT) without aspecific amplification as observed with RT-LAMP using intercalating fluorescent dyes or turbidity readouts [5,7], review see [8,9]. Since DETECTR depends on both signal amplification by RT-LAMP and reporter degradation after Cas12-dependent amplicon recognition (Figure 1), the assay produces a binary readout and is potentially more sensitive and specific compared to qRT-PCR [5,6]. A direct comparison between qRT-PCR and this novel DETECTR assay on a large patient cohort has not yet been performed. In the Netherlands, patients suspected of COVID-19 are admitted under strict isolation procedures to prevent nosocomial transmission of SARS-CoV-2 within the hospital. Unnecessary isolation measures pose a significant burden on the nursing staff as well as on the capacity and costs of the hospital. A rapid highly sensitive SARS-CoV-2 assay, preferably suitable as a POCT, would be of added value for (rapid) clinical decision-making and the optimization of patient flow within the hospital. In this manuscript we describe the development of an in-house SARS-CoV-2 DETECTR assay, compare its performance with routine diagnostic qRT-PCR on almost 400 patient samples of three Dutch hospitals, thereby providing a first field test of this novel Cas12-mediated SARS-CoV-2 detection tool.

**Materials and methods**

All specific information on reagents and relevant concentrations are listed in supplemental tables 1.0-1.6.

**RT-Lamp reaction**

Primers (supplementary Table 1.1) were dissolved in ultrapure water to a final concentration of 100 µM and prepared in 10x primer master mixes (supplementary Table S1.2). For isothermal amplification, 15 µl of complete RT lamp reaction mix was prepared on ice (supplementary Table S1.3) and incubated with 10 µl of isolated RNA or DNA CTRL plasmid at 62°C.
RT-(PCR)-Cas12

RNA extracts derived from COVID-19 positive patients were run in a reverse transcriptase (RT) reaction according to table 1.6 and hence amplified with or without PCR. Next, qRT-PCR as well as RT products were incubated with N-gene RNPs and analyzed via HT-detection as described below.

RNP formation including reporter probe

RNPs were formed by incubating LbCas12 (supplementary Table S1.4) with targeting Guide RNAs in a RNP reaction mix for 30 min at 37°C (supplementary Table S1.5) and subsequently, probe 1,2 or 3 was added in a final concentration of 100 nM (probe 1 and 3) or 500 nM (probe 2).

High throughput (HT) detection

2,5 µl of RT-LAMP reaction mix was incubated with 22,5 µl of RNP complex containing probe 1 or 3, at 37°C for 10 minutes in chimney multi-well plates covered with seals. Readout was performed after 10 minutes of incubation, unless indicated differently in the figure legends, at 37°C in a Biotek Synergy 2 plate reader using a 485/20 excitation and a 528/20 emission filter.

lateral chip assay

2 µl of RT-LAMP reaction mix was incubated with 20 µl of RNP complex containing probe 2, at 37°C for 10 minutes. Next, 80 µl NEBuffer2.1 (1x concentrated) was added. Lateral flow strips were incubated for 2 minutes at RT allowing liquid to migrate. Readout was performed visually.

Statistics

All data was first tested for normality by the Shapiro Wilk test (p=0,05). Data with a gaussian distribution was analyzed with an unpaired two-sided student’s t-test in case of the comparison of 2 samples or an one-way ANOVA with a Dunnett’s post-test in case of 3 samples or more. Data which did not follow a gaussian distribution and contained 3 groups or more, was analyzed with a Kruskall-
Wallis test followed by a Dunnett’s post-test. All statistics were analyzed in Graphpad Prism version 8.0.2.

Patient samples

The majority of patient samples were nasopharyngeal swabs in transport medium, the remainder were either broncheo-alveolar lavage (BAL) or sputum. Extensive description of RNA isolation and qPCR methods can be found in supplemental methods.

Results

Both (RT-)LAMP and Cas12-RNPs can be used to detect RNA/DNA, while the combination potentially increases sensitivity and specificity [6]. We compared the sensitivity of RT-LAMP, RT-Cas12-RNP and DETECTR (combination RT-LAMP/RT-Cas12-RNP, Figure 2A-C; supplemental figure 1A-C). We show that using solely RT-LAMP (figure 2A) or RT-Cas12-RNP (figure 2B and Supplemental figure 1D) did not match the sensitivity of DETECTR (figure 2C, 1E). Of note, the limit of detection (LOD) for RT-LAMP was similar to previously reported [10]. RT followed by Cas12-RNP was not sufficient to detect SARS-CoV-2 RNA in samples with high SARS-CoV-2 viral load (qRT-PCR, Cq-value<20)(Figure 2B). This emphasizes the importance of a separate amplification step (PCR or LAMP) prior to Cas12 detection (Figure 2B-C and Supplemental figure 1D). The added value of Cas12-RNP shows in the improved signal-to-noise ratio, which eases interpretation, compared to RT-LAMP alone (figure 2D). Taken the very large increase in signal to noise ratio (>15 FC) of positive versus negative samples (data distribution is shown in figure 5A (right panel), any plate reader, able to measure the indicated emitted wavelength, will result in similar signal to noise ratio albeit with slightly different fluorescence intensities and fold change values. Interestingly, Cas12-RNP by itself also displays a dependency on target concentration (figure 2B; supplemental figure 2A). This suggests that the RT-LAMP reaction is required to allow sufficient amplification of Cas12-RNP target DNA to allow efficient probe degradation. To investigate the effect of probe length on assay performance, we tested a wide range of SARS-CoV-2 N gene DNA (range 10^{-7} to 10^{16}M) using probes of 8 and 12
nucleotides (nt). The use of a 12 nt probe increased the signal to noise ratio but not the sensitivity of the test (Supplemental Figure 2A-B). The plateau of the fluorescent signal using DETECTR is reached after 10 minutes. However, >75% of the maximum fluorescence is reached within 5 minutes, suggesting that the assay can be performed faster if required (Supplemental Figure 2C). Longer incubation does not increase the fluorescent signal (Supplemental Figure 2D). However, plates can be re-measured or stored for at least three days without significant loss of signal when stored at room temperature in ambient light (Supplemental Figure 2D). In conclusion, our DETECTR data confirm short turn-around-times (<30 minutes including RT-LAMP), signal robustness and ease of result interpretation.

In a pilot experiment we blindly tested a small cohort of patient samples including four positive, four negative and four samples with not interpretable (NI) qRT-PCR results. SARS-CoV-2 RNA was detected in all 4 qRT-PCR positive samples plus 2 qRT-PCR NI samples (Figure 3A-B). Human RNAse P RNA, used as an internal control, was detected in all 12 samples. Hence, DETECTR results were consistent with qRT-PCR, and provided a clear-cut positive (n=2) or negative (n=2) test result for the samples with NI qRT-PCR results. The analytical sensitivity of DETECTR was compared to qRT-PCR using log-scale dilutions of SARS-CoV-2 RNA extracted from patient samples. DETECTR proved 10-100 times more sensitive in 3 out of 4 experiments (Figure 4A, supplemental figure 2E and F). Of note, the observed analytical sensitivity of both tests does not necessarily equal their clinical sensitivity as (potential) inhibitory factors present in patient material have also been diluted. As the Cas12-RNP complex is single nucleotide sensitive [11,12], mutations within the gRNA recognition site may prevent Cas12 detection. Using a dual target approach with gRNAs that anneal to distinct parts of the RT-LAMP generated amplicon could prevent escape from Cas12 detection (supplemental figure 1B). DETECTR results with gRNA1, gRNA2 and combined gRNA1/gRNA2 yielded similar results (Figure 4B). As the risk of aberrant viral variants increases with the ongoing worldwide epidemic, the use of multiple gRNAs is highly recommended. Strong homology within the N-gene of SARS-CoV-2 and other human coronaviruses may compromise the specificity of DETECTR. N-gene homology with
other human coronaviruses varies between 50.1% and 88.2%. The highest concordance is seen with SARS-CoV-1, with a maximum homology of 86.7% in the regions used for the development of RT-LAMP primers and Cas12 gRNA recognition sites. We analyzed 22 samples of patients infected with other human coronaviruses; 22/22 samples tested negative for SARS-CoV-2 and positive for the RNase P housekeeping gene with DETECTR suggesting a specificity of 100% (Figure 4C).

Finally, we tested our DETECTR assay on 378 patient samples derived from three hospitals in the Netherlands. The cohort consisted of RNA extracted from clinical samples of patients that were diagnosed SARS-CoV-2 positive or SARS-CoV-2 negative based on routine qRT-PCR. Our DETECTR assay showed 94.9% (+/- 1.8%/0.8%) concordance with qRT-PCR (figure 5A, 5B), with minor differences between the three centers (Supplemental figure 3; A=94.1%; B=96.7%; C=94.7%). DETECTR positive but qRT-PCR negative samples (n=10) were mainly found in center A (n=9); all 9 samples from this hospital also showed a SARS-CoV-2 band pattern on gel indicating specific product amplification and suggesting they were missed by qRT-PCR (supplemental figure 3D). The DETECTR+/PCR- negative sample of center B was later confirmed SARS-CoV-2 positive by Center B, albeit with Cq-value >35. In total, we found 11 PCR+/DETECTR- samples, 7/11 samples had Cq-values >30 (figure 2B; supplemental Figure 3A-C), but the other four had Cq values of 20.74; 29.78; 29.28 and 28. Re-analysis with an alternative gRNA that anneals to a different part of the N-gene (supplementary Table S1.1) did not yield positive test results, indicating that a mutation within the binding region of the gRNA is unlikely to explain the false negative DETECTR results. An equal number of clinical SARS-CoV-2 positive samples was missed by qRT-PCR (10) and DETECTR (11) indicating similar sensitivity of both approaches in clinical samples. Interestingly screening of patient samples with a non-interpretable qRT-PCR result yielded positive detection of SARS-CoV-2 in 9/19 patient samples (figure 5C), indicating that DETECTR can be used as a fast confirmatory test for samples yielding a NI result in qRT-PCR. Altogether, the overall concordance of around 95% in clinical sensitivity, shows that DETECTR can be used as a specific, fast and reliable technique for patient samples.
Most DETECTR results were obtained using a high throughput 96/384 wells spectrophotometer to detect the cleaved fluorescent probe. A major advantage of DETECTR is that it can be used as an individual POCT using lateral flow strips for read out. Individual lateral flow results (n=40) were 100% concordant with the high throughput results (supplemental figure 4). To confirm robust signals in ‘difficult’ clinical samples, we analyzed 8 samples with not interpretable qRT-PCR results using spectrophotometric and lateral flow detection. Again, fully concordant results: SARS-CoV-2 positive (n=4) and SARS-CoV-2 negative (n=4) (Supplemental Figure 4C). The binary readout is easy to interpret, irrespective of readout method or Cq-value. Therefore, DETECTR POC tests could be used in low-resource countries/regions or as a fast and reliable equipment independent confirmation test to confirm ambiguous qRT-PCR samples.

Discussion

In summary, here we compared DETECTR with qRT-PCR for SARS-CoV-2 diagnosis in a large patient cohort over multiple hospitals and report a 95% accordance. These data are in line with recently published studies where cohorts were tested in a single institute [5,13]. These data are in line with a recently published study where only a small cohort (83 samples) was tested derived from a single hospital. In addition, our data suggest that a 12nt probe is superior over a 8nt probe and we suggest to use a double guide approach to prevent escape from DETECTR due to mutations within amplicons. Overall, DETECTR has comparable sensitivity and superior specificity to qRT-PCR. Our results show that DETECTR represents a reliable, cheap, fast and technically independent alternative to complement qRT-PCR platforms. The low-demand on facility equipment, especially concerning the POCT, makes DETECTR especially suitable for resource low countries/regions. In this paper we
show a LOD for RT-LAMP at 500 copies and for DETECTR at 50 copies. It is however important to note that we have defined the LOD on N-gene plasmids instead of synthetic SARS-CoV-2 RNA. This makes the comparison between RT-LAMP and DETECTR independent of reverse transcriptase efficiency. However, it may not accurately display the LOD of RNA samples, since efficiency to convert RNA to DNA by reverse transcriptase also depends on secondary RNA-structure and sample matrix. Other studies have however shown a similar LOD for RT-LAMP as reporter here after spiking synthetic viral RNA into different matrices, such as mucin or blood [10]. A current limitation of DETECTR is the dependence on three separate reactions, namely RNA isolation, RT-LAMP amplicon amplification and Cas12 mediated reporter degradation. The latter has to be considered a step back in comparison to qRT-PCR, where post amplification handling, a major risk in causing false positive results by contamination, could be removed from the workflow. Further research should focus on integrating all DETECTR steps, including RNA-isolation, into the same reaction tube without post amplification processing. In the current study, the extracted RNA used as input for qRT-PCR was also used for DETECTR. Excitingly, in a recent paper published during the review process, the use of a heat stable Cas12 from *Alicyclobacillus acidiphilus* potentially makes combining the RT-LAMP and Cas12 reactions in one tube possible, which was verified in a test panel including 200 positive patient samples[13]. In addition, these authors showed that RT-LAMP multiplexing of various internal control amplicons together with the viral amplicon in one reaction may be possible, further adding to the robustness of assay results. Of note, onestep RT-LAMP approaches including various RNA extractions have been developed, e.g. for Zika virus[14,15], and compatibility with DETECTR will need to be determined. However, Joung et al. showed that RNA isolation may need to be carried out separately from the RT-LAMP and Cas12 reactions to maintain optimal sensitivity [13]. Importantly, as detection is not compromised upon diluting patient material 10-100 times, the technique may allow the implementation of pooled sample approaches in low-prevalence regions/countries significantly increasing testing capacity (e.g. 20 samples without loss of detection). However, it must be noted that in this patient cohort DETECTR and qRT-PCR were performing on parity. The clinical
sensitivity of DETECTR could be lower despite its higher analytical sensitivity (Figure 1F, 1H) due to the matrix of clinical samples having a more profound inhibitory effect on DETECTR technology. Importantly, once implemented the suggested approach can be easily diverted to screen other existing or emerging pathogens or any other platform that requires identification based on specific DNA/RNA [6,11,12]. The DETECTR test helps to optimize diagnostic strategies for both bedside and high-throughput settings leading to an increase in testing capacity and improved diagnostic evaluation, ultimately leading to better determination of endemic progression facilitating governmental policy decisions.
Acknowledgements

This study was supported by a NWO-ZONMW “creative solutions to battle COVID-19” grant from the Dutch government (No.5000.9954). We would like to thank the individuals part of the studied cohort.

Authorship contributions

EB and HV performed the RT-LAMP, DETECTR assays. MC, TvdL, EC and JS collected the cohort material, isolated RNA and performed the qRT-PCR on validated platforms. EvdA supervised the study. All authors contributed in writing the manuscript, which was critically reviewed by all authors.

Conflict of interest

The authors report no conflict of interest
**Figure legends**

**Figure 1: Graphic representation of DETECTR assay**

RNA is converted to cDNA and amplified in one reaction mix for 20 minutes using RT-LAMP. Next, Cas12 RNPs are added that recognize and cleave SARS-CoV-2 amplified products leading to activation of Cas12. Activated Cas12 destroys the single stranded linker DNA between quencher and probe leading to fluorescence that can be detected on indicated platforms. ***=p<0.001; ****=p<0.0001 using ANOVA and Dunnett’s post-test

**Figure 2: Combining RT-LAMP and Cas12 improves sensitivity of SARS-CoV-2 detection**

(A-D) Specific N-gene plasmid copy concentrations (A,C) or confirmed RNA from SARS-CoV-2 positive individuals with indicated range of qRT-PCR cq-values (B) were run in a RT-LAMP reaction (A), RT-Cas12 (B) or RT-LAMP-Cas12 (DETECTR, C) assays using an amplicon within the N-gene and a gRNA annealing to that amplicon (supplemental figure 1). Note that whereas the RT-LAMP reaction results in a fluorescence signal proportional to the input (A), the combination of RT-LAMP/Cas12-RNP results in a binary test outcome with a high signal to noise ratio (24 times on average) due to the degradation of the reporter probe, which depends on the induced nuclease activity of Cas12 (C). D) shows the fold change in fluorescence normalized to the negative control.

**Figure 3: DETECTR accurately identifies SARS-CoV-2 in clinical samples**

A) a cohort of 12 patient RNA isolates, including 4 RT-PCR positive, 4 RT-PCR and clinically negative and 4 NI were screened with DETECTR (the convention of a NI (not interpretable) result can be found in material and methods). Bars represent the average of a duplicate and error bars the SD (N-gene (red) and internal control RNAseP (black)). B) shows the comparison of qRT-PCR result and DETECTR fluorescence signal (red positive samples; grey negative samples; white NI.)
Figure 4: RT-LAMP/Cas12 is a specific and sensitive test to detect SARS-CoV-2.

A) Log scale dilutions of SARS-CoV-2 positive patient samples were tested with qRT-PCR and DETECTR in indicated log dilutions were + indicates a positive result and – a negative test result. (B) Two gRNAs with distinct annealing sites were tested in the DETECTR assay. The dot plot shows the fluorescence signal of positive (red) and negative samples (black). Numbers indicate the number of negatives and positives samples analyzed. C) A collection of non-SARS-CoV-2 corona strains samples confirmed by qRT-PCR were found to be negative using SARS-CoV-2 specific DETECR. ****=p<0.0001 using two-sided unpaired T-test.

Figure 5 High level concordance between qRT-PCR and DETECTR.

A) 378 qRT-PCR confirmed SARS-CoV-2 tested samples from different centers were compared to the results obtained using DETECTR. The matrix displays the results from the DETECTR assay (vertical) compared to the qRT-PCR results (horizontal). The graph shows the fluorescence intensity (left graph) and fold change fluorescence signal normalized to a negative control (right graph) with each dot representing a DETECTR test on RNA from a different individual. B) Subclassification based on qRT-PCR cq-values compared to DETECR result. C) DETECTR on 19 samples that gave an NI results by qRT-PCR (convention of NI can be found in Material and Methods). Orange bars: N-gene DETECTR; black bars: RNaseP control DETECTR. ****=p<0.0001 using Kruskal-Wallis test, followed by a Dunnett’s post-test, comparing all groups with the ‘True negatives’ group.
References

[1] J. Phua, L. Weng, L. Ling, et al., “Fast and Chronic Programmes Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,” Rev. Lancet Respir Med, vol. 8, pp. 506–517, 2020.

[2] WHO, “Key facts about major deadly diseases Managing epidemics,” 2020.

[3] E. Isere, A. Fatiregun, and I. Ajayi, “An overview of disease surveillance and notification system in Nigeria and the roles of clinicians in disease outbreak prevention and control,” Niger. Med. J., vol. 56, no. 3, p. 161, 2015.

[4] L. Jones, G. Bates, E. McCoy, C. Beynon, J. McVeigh, and M. A. Bellis, “Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: A systematic review,” Eur. J. Public Health, vol. 24, no. 5, pp. 781–788, Oct. 2013.

[5] J. P. Broughton, X. Deng, G. Yu, et al., “CRISPR–Cas12-based detection of SARS-CoV-2,” Nat. Biotechnol., vol. 38, no. 7, pp. 870–874, Jul. 2020.

[6] J. S. Chen, E. Ma, L. B. Harrington, et al., “CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity,” Science (80-. ), vol. 360, no. 6387, pp. 436–439, Apr. 2018.

[7] T. Notomi, H. Okayama, H. Masubuchi, et al., “Loop-mediated isothermal amplification of DNA,” Nucleic Acids Res., vol. 28, no. 12, pp. i–Vii, 2000.

[8] A. S. James and J. I. Alwneh, “COVID-19 Infection Diagnosis: Potential Impact of Isothermal Amplification Technology to Reduce Community Transmission of SARS-CoV-2,” Diagnostics, vol. 10, no. 6, p. 399, Jun. 2020.

[9] G. Biswas and M. Sakai, “Loop-mediated isothermal amplification (LAMP) assays for detection and identification of aquaculture pathogens: Current state and perspectives,” Applied Microbiology and Biotechnology, vol. 98, no. 7 Springer Verlag, pp. 2881–2895, Jan. 30, 2014.

[10] M. Jiang, W. Pan, A. Arasthfer, et al., “Development and Validation of a Rapid, Single-Step Reverse Transcriptase Loop-Mediated Isothermal Amplification (RT-LAMP) System Potentially to Be Used for Reliable and High-Throughput Screening of COVID-19,” Front. Cell. Infect. Microbiol., vol. 10, p. 331, Jun. 2020.

[11] J. S. Gootenberg, O. O. Abudayyeh, J. W. Lee, et al., “Nucleic acid detection with CRISPR-Cas13a/C2c2,” Science (80-. ), vol. 356, no. 6336, pp. 438–442, Apr. 2017.

[12] J. S. Gootenberg, O. O. Abudayyeh, M. J. Kellner, J. Joung, J. J. Collins, and F. Zhang, “Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a and Csm6,” Science (80-. ), vol. 360, no. 6387, pp. 439–444, Apr. 2018.

[13] J. Joung, A. Ladha, M. Saito, et al., “Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing,” N. Engl. J. Med., p. NEJMc2026172, Sep. 2020.

[14] L. E. Lamb, S. N. Bartolone, M. O. Tree, et al., “Rapid Detection of Zika Virus in Urine Samples and Infected Mosquitos by Reverse Transcription-Loop-Mediated Isothermal Amplification,” Sci. Rep., vol. 8, no. 1, Dec. 2018.
[15] S. J. R. Da Silva, K. Pardee, and L. Pena, “Loop-mediated isothermal amplification (LAMP) for the diagnosis of Zika virus: A review,” *Viruses*, vol. 12, no. 1. MDPI AG, Dec. 23, 2019.

[16] M. Goujon, H. McWilliam, W. Li, et al., “A new bioinformatics analysis tools framework at EMBL-EBI,” *Nucleic Acids Res.*, vol. 38, no. SUPPL. 2, pp. 695–699, 2010.

[17] S. Elbe and G. Buckland-Merrett, “Data, disease and diplomacy: GISAID’s innovative contribution to global health,” *Glob. Challenges*, vol. 1, no. 1, pp. 33–46, Jan. 2017.

[18] V. M. Corman, O. Landt, M. Kaiser, et al., “Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,” *Eurosurveillance*, vol. 25, no. 3, p. 2000045, Jan. 2020.
| Table 1.0 |
|-----------|-----------|
| **Vendor** | **cat** |
| Oligos, probes, sgRNA | IDT | na |
| Ultra pure DNAse and Rnase free water | invitrogen | 10977-035 |
| NaCl | Merck | 106404 |
| Sodium acetate | Sigma Aldrich | S8625 |
| EDTA | Sigma Aldrich | E5134-5009 |
| TCEP | Sigma Aldrich | E4706 |
| Glycerol | Sigma Aldrich | G6279-1L |
| LbCas12a | NEB | M0653 |
| N-gene plasmid (2019-nCov-Npostive | IDT | 10006625 |
| Lateral flow strips | TwistDx | MILENIA01 |
| RT-LAMP mastermix | NEB | E1700L |
| Chimney 96 wells Plates (black) | Greiner Bio | 655209 |
| Chimney 384 wells Plates (black) | Greiner Bio | 781076 |
| MicroAmp optical adhesive film | Thermo | 431197 |
| Superscript III first strand Reverse transcriptase | Thermo Fisher | 18080-051 |
| Phusion High-Fidelity PCR kit | Thermo Scientific | MAN0013363 |
| application | specific name | sequence |
|-------------|---------------|----------|
| isothermal amplification | N-geneF3 | AACACAAGCTTTCGGCAG |
| isothermal amplification | N-geneB3 | GAAATTTGGATCTTTGTGATCC |
| isothermal amplification | N-geneFIP | TCCGGGCAAATGTTGGTTAATCGCAAGAAATTTGGGGAC |
| isothermal amplification | N-geneBIP | CGCATTTGGCATGGAAGTCACTTTTGATGGCACCTGTGTAG |
| isothermal amplification | N-geneLF | TTCTTGTCTGATTAATTC |
| isothermal amplification | N-geneLB | ACCTTCGGGAACGCTGTT |
| isothermal amplification | RNasePPOP7F3* | TTGATGAGCTGAGCCA |
| isothermal amplification | RNasePPOP7B3* | CACCCTCAATGCAAGTC |
| isothermal amplification | RNasePPOP7FIP* | GTGTGACCCTGAAAGACTCGTGGTTAGCCACTGACTCGGATC |
| isothermal amplification | RNasePPOP7BIP* | CCTCCGTGATATGGCTCTTCGTTTTTTTCTTACATGGCCTCTGGTC |
| isothermal amplification | RNasePPOP7LF* | ATGTGGATGCTGAGCTGTT |
| isothermal amplification | RNasePPOP7LB* | CATGCTGAGCTCCTGAGAC |
| N gene detection | Guide 1 | CCCCCAGCGCTTACCTGGACCTGGAC |
| N gene detection | Guide 2 | GGGACGGAACCTAACTGGAC |
| RNAse P detection | RnasePgRNA(ctrl) | AATTACTTGGGTGTGACCCT |
| 8nt probe DETECTR-HT POCT PAMreporter-HT | /5FAM/TTATTATT/3IABkFQ |
| 12nt probe DETECTR-HT POCT PAMreporter-HT | /5FITC/TTATTATT/3Bio/ |
### Table 1.2

| Primer          | Description                  | Volume (µl) | Final concentration (µM) |
|-----------------|------------------------------|-------------|--------------------------|
| COVID-19_1      | N-gene F3 primer (100 uM)    | 20          | 2                        |
| COVID-19_2      | N-gene B3 primer (100 uM)    | 20          | 2                        |
| COVID-19_3      | N-gene FIP primer (100 uM)   | 160         | 16                       |
| COVID-19_4      | N-gene BIP primer (100 uM)   | 160         | 16                       |
| COVID-19_5      | N-gene LF primer (100 uM)    | 80          | 8                        |
| COVID-19_6      | N-gene LB primer (100 uM)    | 80          | 8                        |
|                 | ultrapure water              | 480         |                          |

| Primer          | Description                  | Volume (µl) | Final concentration (µM) |
|-----------------|------------------------------|-------------|--------------------------|
| COVID-19_13     | Rnase P F3 primer            | 20          | 2                        |
| COVID-19_14     | Rnase P B3 primer            | 20          | 2                        |
| COVID-19_15     | Rnase P FIP primer           | 160         | 16                       |
| COVID-19_16     | Rnase P BIP primer           | 160         | 16                       |
| COVID-19_17     | Rnase P LF primer            | 80          | 8                        |
| COVID-19_18     | Rnase P LB primer            | 80          | 8                        |
|                 | ultrapure water              | 480         |                          |
| Reagent                                         | Volume 1 rnx (µL) |
|------------------------------------------------|------------------|
| RT-LAMP mastermix (NEB)                        | 12.5             |
| 10x primer mix (N-gene, POP7 or E-gene)        | 2.5              |
| Nuclease free water                            | 5                |
| **Total Volume**                               | **20**           |
Table 1.4

| Cas12 storage buffer | final concentration |
|-----------------------|---------------------|
| NaCl                  | 500 mM              |
| sodium acetate        | 20 mM               |
| EDTA                  | 1 mM                |
| TCEP                  | 1 mM                |
| Glycerol              | 50% v/v             |

Ultra pure DNase and Rnase free water na

pH 6.0 @ 25°C

---

| general stock          |                |                |
|------------------------|----------------|----------------|
| dry weight (pmol)      | Cas12A storage buffer (µl) | Final concentration (µM) |
| lbcas12a (NEB M06537T) | 2000           | 2000           | 100            |

---

| Working solution       |                |                |
|------------------------|----------------|----------------|
| Volume of general stock (µl) | Cas12A storage buffer (µl) | Final concentration (µM) |
| lbcas12a (general stock)  | 10             | 1990           | 0.5            |
Table 1.5

| RNP formation mix for 1 condition | volume in µl | final concentration |
|----------------------------------|--------------|---------------------|
| Nuclease free water              | 14           | 0                   | na                  |
| 10X NEBuffer 2.1                 | 2            | 0                   | 1X                  |
| 0.5 µM Ibcas12a                  | 2            | 0                   | 50 nM               |
| 0.625 µM gRNA (N-gene)           | 2            | 0                   | 62.5 nM             |
| Total volume                     | 20           | 0                   |                     |

incubate RNP reaction mix for 30 minutes at 37oC

add probe
| RT-Mix 1 | Superscript III first strand Reverse transcriptase | Volume/rxn (µl) |
|----------|-----------------------------------------------|----------------|
|          | Total RNA                                      | 5              |
|          | 10 µm Primer Fw N-geneF3 AACACAAGCTTTCGGCAG    | 0.5            |
|          | 10 µm Primer Rv N-geneB3 GAAATTTGGATCTTTGTCATCC | 0.5            |
|          | 10 mM dNTP mix                                 | 1              |
|          | MQ                                            | 3              |
|          | **Total**                                      | **10**         |

| RT-Mix 2 | Superscript III first strand Reverse transcriptase | Volume/rxn (µl) |
|----------|-----------------------------------------------|----------------|
|          | 10X RT buffer                                 | 2              |
|          | 25mM MgCl2                                    | 4              |
|          | 0.1 M DTT                                     | 2              |
|          | RNaseOUT (40U/uL)                             | 1              |
|          | Superscript III RT (200U/uL)                  | 1              |
|          | **Total**                                      | **10**         |

1. Combine the components of mix 1
2. Incubate at 65°C for 5 min
3. Place on ice for 1 min
4. Prepare cDNA synthesis mixes according to mix 2
5. Add 10 uL of cDNA synthesis mix to each well and mix
6. Incubate for 50 min at 50°C
7. Terminate the reaction at 85°C for 5 min
8. Spin down briefly
9. Add 1 uL of RNase H to each tube and incubate for 20 min at 37°C

| RT-PCR Mix          | Phusion High-Fidelity PCR Kit | Volume/rxn (µl) |
|---------------------|------------------------------|-----------------|
| H2O                 |                              | 12.4            |
| 5X Phusion HF Buffer|                              | 4               |
| 10 mM dNTPs         |                              | 0.4             |
| 10 µm Primer Fw     | N-geneF3                     | 0.5             |
| 10 µm Primer Rv     | N-geneB3                     | 0.5             |
| RT-template         |                              | 2               |
| HF phusion polymerase|                             | 0.2             |
| **Total**           |                              | **20**          |

| PCR program         |                             |
|---------------------|-----------------------------|
| time in seconds     | degrees                     |
| 1                   | 30                          | 98              |
| 2                   | 15                          | 58              |
|                     |                             | **35 cycly**    |
|   |   |   |
|---|---|---|
| 3 | 10 | 72 |
| 1 | Combine the components of RT-PCR Mix |
| 2 | Run PCR according PCR program |
| 3 | run fragments on 2% Agarose gel for 30 minutes 130v |
Figure 1

**RNA amplification**

- Human + SARS-CoV-2
- 20 minutes (62°C)

**Targeting and detection**

- Cas12
- Emission
- 10 minutes (37°C)

- A) DETECTR-High throughput
  - 488nm
- b) DETECTR-Point of care
  - ctrl
  - SARS-CoV-2
Figure 2

A  
RT-LAMP

B  
RT-Cas12

C  
RT-LAMP + Cas12 (DETECTR)

D  
RT-LAMP (black circles) vs. RT-LAMP + Cas12 (DETECTR) (red circles)
**Figure 3**

A. Percentage of SARS-CoV-2 mRNA detected in RNA extracts from 12 different patient samples obtained at the time of clinical symptom onset. Black bars represent detection of RNase P RNA (negative control), and red bars represent detection of the N-gene (positive control). Error bars represent standard deviation.

B. Results of qRT-PCR and DETECTR score for patient samples.
Figure 4

A

| Dilution | Patient 1 | Patient 2 |
|----------|-----------|-----------|
| 1:10     | +         | +         |
| 1:10²    | +         | +         |
| 1:10³    | +         | +         |
| 1:10⁴    | +         | -         |
| 1:10⁵    | -         | +         |
| 1:10⁶    | -         | +         |
| 1:10⁷    | -         | -         |

B

Fluorescence intensity (AU)

C

| CoV-229E  | Average Ct Value | Range Ct Value | DETECTR SARS-CoV-2 |
|-----------|------------------|----------------|--------------------|
|           | 28,8             | 28,8-28,8      | 0/1                |
| CoV-HKU1  | 24,0             | 17,7-33,7      | 0/10               |
| CoV-NL63E | 30,0             | 25,6-32,2      | 0/7                |
| CoV-OC43  | 31,6             | 27,9-33,8      | 0/4                |
Figure 5

A

| DETECTR | qRT-PCR |
|---------|---------|
|         | Negative | Positive |
| Negative | 213      | 11       |
| Positive | 10       | 144      |

B

| Average Cq Value | Range Cq Value | DETECTR result | SARS-CoV-2 |
|------------------|----------------|----------------|------------|
| <15              | <15.0          | 1/1            | 1/1        |
| 15-20            | 15.0-19.4      | 16/16          | 16/16      |
| 20-25            | 20.3-23.7      | 36/37          | 36/37      |
| 25-30            | 25.0-29.9      | 61/64          | 61/64      |
| 30-32            | 30.0-31.9      | 24/25          | 24/25      |
| >32              | 32.1-37.3      | 6/12           | 6/12       |

C

- **RNase P**
- **N-gene**